Onyx Pharmaceuticals to Acquire Proteolix
Onyx Pharmaceuticals has agreed to purchase private biotechnology company Proteolix for $276 million in cash.
Featured Articles
Positive Phase II Data for Peregrine’s Lung Cancer Treatment
Peregrine Pharmaceuticals reported positive Phase II data in a clinical trial of bavituximab in patients with a deadly form of lung cancer.
Biotech News Out of Quebec
Medicago, a Canadian company focused on protein-based vaccines, has signed a contract with the U.S. Army to investigate ways to create biofuels from plants.
Two Pharma Companies to Offer Discounted Shares
Repros and Targacept have announced plans to offer shares in their respective companies at a reduced cost.
Inovio Biomedical (AMEX: INO): A DNA Vaccine Delivery Innovator
Inovio Biomedical (AMEX: INO) is developing a robust pre-clinical and early clinical stage pipeline of innovative DNA-based vaccines and therapeutics that target cancer, influenza, and other infectious diseases (e.g. HIV) based on its SynCon DNA vaccine construct and electroporation DNA delivery technology platforms.
MedTech Sentinal Special Edition Advamed 2009 Presenting Companies by Tasmia Khan The line up of medical device companies presenting at Advamed 2009 has been set. Forty-eight companies will […]
Acadia and Biovail Not Giving Up on Parkinson’s Drug
Acadia and its partner Biovail made news last month with a failed late-stage trial of pimavanserin, their experimental drug candidate to treat psychosis related to Parkinson’s disease.
CardiAQ Valve Technologies Announces New Data, New Board Members
CVT’s system, currently under development, is the first self-conforming and self-anchoring technology for transcatheter mitral valve implantation (TVMI).
Three Companies Race for Obesity Drug Approval
The race for an anti-obesity drug intensified Wednesday with the latest mid-stage trial data from Orexigen Therapeutics.
BioSante (NASDAQ: BPAX): LibiGel Provides Big Upside Potential
On 9/22/09, BioSante and Cell Genesys (NASDAQ: CEGE) announced that they have determined the final exchange ratio will be 0.1828 in connection with the previously announced merger between the companies.